Free Trial

Tarsus Pharmaceuticals (TARS) Stock Price, News & Analysis

Tarsus Pharmaceuticals logo
$58.16 +0.34 (+0.59%)
Closing price 04:00 PM Eastern
Extended Trading
$58.12 -0.03 (-0.06%)
As of 06:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Tarsus Pharmaceuticals Stock (NASDAQ:TARS)

Key Stats

Today's Range
$57.73
$58.70
50-Day Range
$38.82
$58.85
52-Week Range
$25.82
$58.95
Volume
409,669 shs
Average Volume
657,648 shs
Market Capitalization
$2.45 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$66.67
Consensus Rating
Buy

Company Overview

Tarsus Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
36th Percentile Overall Score

TARS MarketRank™: 

Tarsus Pharmaceuticals scored higher than 36% of companies evaluated by MarketBeat, and ranked 750th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Tarsus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Tarsus Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Tarsus Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Tarsus Pharmaceuticals are expected to grow in the coming year, from ($3.17) to ($1.44) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Tarsus Pharmaceuticals is -24.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Tarsus Pharmaceuticals is -24.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Tarsus Pharmaceuticals has a P/B Ratio of 7.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Tarsus Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    21.18% of the float of Tarsus Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Tarsus Pharmaceuticals has a short interest ratio ("days to cover") of 12.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Tarsus Pharmaceuticals has recently decreased by 0.85%, indicating that investor sentiment is improving.
  • Dividend Yield

    Tarsus Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Tarsus Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    21.18% of the float of Tarsus Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Tarsus Pharmaceuticals has a short interest ratio ("days to cover") of 12.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Tarsus Pharmaceuticals has recently decreased by 0.85%, indicating that investor sentiment is improving.
  • News Sentiment

    Tarsus Pharmaceuticals has a news sentiment score of 1.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for Tarsus Pharmaceuticals this week, compared to 6 articles on an average week.
  • Search Interest

    Only 2 people have searched for TARS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Tarsus Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Tarsus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $300,000.00 in company stock.

  • Percentage Held by Insiders

    Only 8.97% of the stock of Tarsus Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    90.01% of the stock of Tarsus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Tarsus Pharmaceuticals' insider trading history.
Receive TARS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tarsus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TARS Stock News Headlines

Biotech - Genetic Graphic
3 Biotech Catalysts Present Major Opportunity (TARS)
Three promising biotech names stand out for potentially catalyzing drugs currently on the market or in development; here's why they may rally further.
An $8 trillion-dollar discovery 17,000 ft underwater
A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materials critical for AI chips, EV batteries, smartphones, and advanced weapons systems. While few people know about these metals, global powers—including the U.S., China, and Russia—are racing to secure them. And one tiny public company, recently backed by the U.S. government, holds mining rights to over 340 million tons… and near-monopoly access to the richest zone.tc pixel
Tarsus to Participate in Upcoming Investor Conferences
See More Headlines

TARS Stock Analysis - Frequently Asked Questions

Tarsus Pharmaceuticals' stock was trading at $55.37 at the beginning of 2025. Since then, TARS stock has increased by 5.0% and is now trading at $58.16.

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) issued its earnings results on Wednesday, August, 6th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by $0.15. The company had revenue of $102.66 million for the quarter, compared to the consensus estimate of $95.81 million. Tarsus Pharmaceuticals had a negative trailing twelve-month return on equity of 32.36% and a negative net margin of 31.13%.
Read the conference call transcript
.

Tarsus Pharmaceuticals (TARS) raised $80 million in an IPO on Friday, October 16th 2020. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Jefferies and Raymond James served as the underwriters for the IPO and LifeSci Capital and Ladenburg Thalmann were co-managers.

Tarsus Pharmaceuticals' top institutional shareholders include Jennison Associates LLC (5.87%), Assenagon Asset Management S.A. (2.37%), Geode Capital Management LLC (2.22%) and Invesco Ltd. (2.20%). Insiders that own company stock include Bobak R Azamian, Seshadri Neervannan, Aziz Mottiwala, Bryan Wahl, Dianne C Whitfield, Leonard M Greenstein, Elizabeth Yeu Lin, Mark J Holdbrook, Andrew D Goldberg and Jose M Trevejo.
View institutional ownership trends
.

Shares of TARS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Tarsus Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

Last Earnings
8/06/2025
Today
8/28/2025
Next Earnings (Estimated)
11/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TARS
CIK
1819790
Fax
N/A
Employees
50
Year Founded
N/A

Price Target and Rating

High Price Target
$84.00
Low Price Target
$51.00
Potential Upside/Downside
+14.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.33)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$115.55 million
Net Margins
-31.13%
Pretax Margin
-31.13%
Return on Equity
-32.36%
Return on Assets
-21.04%

Debt

Debt-to-Equity Ratio
0.22
Current Ratio
5.26
Quick Ratio
5.21

Sales & Book Value

Annual Sales
$182.95 million
Price / Sales
13.47
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.88 per share
Price / Book
7.41

Miscellaneous

Outstanding Shares
42,210,000
Free Float
38,427,000
Market Cap
$2.47 billion
Optionable
Optionable
Beta
0.79

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:TARS) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners